|
|
|
|
|
|
|
|
|
|
Biotech
Nov 10, 2016
IBM Watson is kicking off another oncology partnership, this time with the Broad Institute of MIT and Harvard University. The $50 million tie-up will have the pair examining genome data from 10,000 drug-resistant tumors and cell line studies, with the goal of understanding the drivers behind cancer drug resistance and developing new treatments.....
Unlike earlier studies, this project will have a broad focus rather than pinpoint a specific cancer,
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.